Diabetes Biotech Seeks $5M for Novel Oral Therapy

Melbourne-based ImmunoBiota Therapeutics is advancing a groundbreaking approach to type 1 diabetes (T1D) treatment, aiming to halt the autoimmune attack at its source rather than merely managing symptoms. The company is currently seeking $5 million in Seed funding to propel its lead candidate, IBT-100, into crucial clinical trials. This funding round is earmarked to support the next phase of development, including regulatory preparations for a planned $25 million Series A and a future public offering on the ASX.

Founded in 2022 by immunologist Dr. Eliana Marino, a spinout from Monash University, ImmunoBiota is developing IBT-100 as the world's first oral, non-immunosuppressive therapy for T1D. Unlike existing treatments that often require lifelong insulin injections and can involve broad immune suppression, IBT-100 is designed to be administered orally, potentially mixed into a drink. The therapy targets the gut, delivering naturally occurring metabolites to the colon with the aim of retraining the immune system to cease its assault on insulin-producing pancreatic beta cells.

The global burden of type 1 diabetes continues to grow, with millions worldwide relying on complex management regimens. The market for T1D therapeutics, while dominated by insulin, is ripe for innovation that addresses the underlying disease mechanism. ImmunoBiota's strategy represents a significant departure from conventional T1D management, which has historically focused on mitigating the consequences of the disease. Dr. Marino emphasized this paradigm shift, stating, "For decades we’ve treated the consequences of type 1 diabetes. We’re trying to intervene where the disease begins."

Early human studies involving 18 adults with established T1D have demonstrated that IBT-100 is safe and well-tolerated over a six-week treatment period and subsequent 12-week follow-up. While this initial study was not designed to prove efficacy in halting or reversing the disease, it did reveal biological changes consistent with the company's therapeutic hypothesis. These promising safety and tolerability data provide a strong foundation for advancing IBT-100 into pediatric trials.

The planned Phase 1b/2a trial in children, slated to commence in late 2027, will be a critical step in validating the efficacy of IBT-100. The successful completion of this trial could position ImmunoBiota Therapeutics as a leader in a new wave of autoimmune disease treatments. The company's founder, Dr. Eliana Marino, recently garnered recognition for her work, winning the $100,000 excellence in innovation award at the Diabetes Australia Grand Innovation Challenge, underscoring the potential impact of her research.

The broader biotechnology sector, particularly in Australia, has seen increased investor interest in companies developing novel therapies for chronic conditions. With the T1D market representing a significant unmet need, ImmunoBiota's innovative oral, non-immunosuppressive approach holds considerable promise. The company's strategic fundraising plan, culminating in a potential ASX listing, signals ambitious growth objectives and a clear path toward commercialization.